

From: Executive Board, Boon Labs

To: [REDACTED]

Date: [REDACTED]

Subject: Contingency Planning – Dr. Varma

All,

It has come to our attention that Dr. Varma is refusing to comply with the agreed-upon terms regarding VX-47. His resistance to the distribution and monetization strategy discussed with the Pharma Consortium presents a substantial liability to our long-term interests.

Considering the sensitive nature of his research and the extent of his knowledge, we must discuss possible solutions to ensure continuity without his interference. We will convene at [REDACTED] to determine an appropriate course of action.

Failure to secure his cooperation is not an option.

- [REDACTED]
Boon Labs Executive Board